DUBLIN--(BUSINESS WIRE)--The "Global Sickle Cell Anemia Therapeutics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Global Sickle Cell Anemia Therapeutics market is expected to reach $5,567.75 million by 2026 growing at a CAGR of 12.5% during the forecast period. Sickle-cell anaemia is a disease which is categorized by the existence of sickle-shaped erythrocytes. Sickle-cell anaemia is an inherited, lifelong blood disorder that impacts haemoglobin causing serious damage to the body.
Some of the key factors driving the growth of sickle-cell anaemia therapeutics market are the unmet medical needs and the increase in sickle-cell diseases. However, the side effects associated with current therapies and low awareness among individuals will surely impede the growth of this market.
Based on the Product Type, the pharmacotherapy segment is estimated to have a lucrative growth due to the potential launch of promising pipeline candidates such as Voxelotor, Crizanlizumab, Rivipansel, and Altemia. It is also estimated to lead the market, owing to a strong pipeline and several promising drug launches throughout the forecast period.
The key vendors mentioned are Addmedica, Baxter, Bioverativ, Bluebird Bio, Bristol-Myers, Squibb, Daiichi Sankyo, Eli Lilly, Emmaus Medical, Gamida Cell, Gilead Sciences, Global Blood Therapeutics, GlycoMimetics, HemaQuest Pharmaceuticals, Imara, Ironwood Pharmaceuticals, Johnson & Johnson, Mast Therapeutics, Merck Sharp & Dohme, Micelle BioPharma, and Modus Therapeutics.
Key Questions Answered in this Report:
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
-
Fastest growing markets analyzed during the forecast period
Key Topics Covered:
1 Market Synopsis
2 Research Outline
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Sickle Cell Anemia Therapeutics Market, By Medication
5.1 Introduction
5.2 Antibiotics
5.3 Hydroxyurea
5.4 Pain-Relieving Medications
5.5 Folic Acids
5.6 Antimetabolites
5.7 Vaccines
5.8 Analgesics
5.9 Other Medications
6 Global Sickle Cell Anemia Therapeutics Market, By Therapy
6.1 Introduction
6.2 Hydroxyurea
6.3 L-Glutamine
7 Global Sickle Cell Anemia Therapeutics Market, By Product Type
7.1 Introduction
7.2 Blood Transfusion
7.3 Bone Marrow Transplant
7.4 Gene Therapy
7.5 Pharmacotherapy
8 Global Sickle Cell Anemia Therapeutics Market, By Application
8.1 Introduction
8.2 Adult
8.3 Child
9 Global Sickle Cell Anemia Therapeutics Market, By End User
9.1 Introduction
9.2 Government
9.3 Home Healthcare
9.4 Hospitals
9.5 Infusion Centers
9.6 Private Clinics
9.7 Other End Users
10 Global Sickle Cell Anemia Therapeutics Market, By Geography
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 South America
10.5 Middle East & Africa
11 Strategic Benchmarking
12 Vendors Landscape
12.1 Addmedica
12.2 Baxter
12.3 Bioverativ
12.4 Bluebird Bio
12.5 Bristol-Myers Squibb
12.6 Daiichi Sankyo
12.7 Eli Lilly
12.8 Emmaus Medical
12.9 Gamida Cell
12.10 Gilead Sciences
12.11 Global Blood Therapeutics
12.12 GlycoMimetics
12.13 HemaQuest Pharmaceuticals
12.14 Imara
12.15 Ironwood Pharmaceuticals
12.16 Johnson & Johnson
12.17 Mast Therapeutics
12.18 Merck Sharp & Dohme
12.19 Micelle BioPharma
12.20 Modus Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/kdd40y
